SCHEMBL1995850

SCHEMBL1995850

COc1nc(Cl)nc2ccccc12

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1I3 Q14994 2/20 0.56
MAPK1 P28482 1/20 0.56
MAPT P10636 2/20 0.54
POLB P06746 1/20 0.52
EGFR P00533 2/20 0.51
PDGFRB P09619 2/20 0.51
KDR P35968 2/20 0.51
CYP1A2 P05177 3/20 0.50
CYP3A4 P08684 1/20 0.50
VDR P11473 1/20 0.50
CYP2C9 P11712 1/20 0.50
CYP2B6 P20813 1/20 0.50
AHR P35869 1/20 0.50
ALDH1A1 P00352 3/20 0.49
KDM4E B2RXH2 2/20 0.49
CYP2C19 P33261 2/20 0.47
MAOA P21397 1/20 0.47
MAOB P27338 1/20 0.47
ADORA3 P0DMS8 1/20 0.46
HPGD P15428 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3552942 0.80 L3MBTL1 (0.64) MAPK1MAPTPOLBCYP1A2CYP2C9
SCHEMBL18913911 0.80 KDM4E (0.45) NR1I3MAPK1MAPTPOLBEGFR
SCHEMBL15147752 0.79 LMNA (0.64) MAPTPOLBKDRCYP1A2CYP2C9
SCHEMBL317214 0.78 MAPT (0.56) NR1I3MAPK1MAPTPOLBCYP1A2
SCHEMBL29487316 0.78 MAPT (0.56) NR1I3MAPK1MAPTPOLBCYP1A2
SCHEMBL6042690 0.78 LMNA (0.68) NR1I3MAPK1MAPTPOLBEGFR
SCHEMBL10753288 0.78 MAT2A (0.49) NR1I3MAPK1ALDH1A1KDM4EHPGD
SCHEMBL7048658 0.78 CYP1A2 (0.58) NR1I3MAPK1MAPTPOLBCYP1A2
Hydrochloric Acid SCHEMBL28183130 0.77 LMNA (0.66) NR1I3MAPK1MAPTPOLBEGFR
Hydrochloric Acid SCHEMBL8442906 0.77 MAPT (0.54) NR1I3MAPK1MAPTPOLBCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025073583-A1 PARP1 INHIBITOR COMPOUNDS Duke Street Bio Limited (GB) 2025-04-10 WO disclosed
CN-110551125-A Preparation method of rutaecarpine derivative UNIV CHANGZHOU 2019-12-10 CN disclosed
US-8937078-B2 Quinazolinones as prolyl hydroxylase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2015-01-20 US disclosed
US-20130216498-A1 IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS ALMIRALL, S.A. (ES) 2013-08-22 US disclosed
US-20130216498-A1 IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS ALMIRALL, S.A. (ES) 2013-08-22 US disclosed
US-20130216498-A1 IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS ALMIRALL, S.A. (ES) 2013-08-22 US disclosed
EP-2516436-A1 IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS Almirall S.A. (ES) 2012-10-31 EP disclosed
US-8044068-B2 Aminopyrrolidine compound TAISHO PHARMACEUTICAL CO., LTD (JP) 2011-10-25 US disclosed
US-8044068-B2 Aminopyrrolidine compound TAISHO PHARMACEUTICAL CO., LTD (JP) 2011-10-25 US disclosed
US-8044068-B2 Aminopyrrolidine compound TAISHO PHARMACEUTICAL CO., LTD (JP) 2011-10-25 US disclosed
US-20100204226-A1 QUINAZOLINONES AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2010-08-12 US disclosed
US-20090291940-A1 AMINOPYRROLIDINE COMPOUND TAISHO PHARMACEUTICAL CO., LTD. (JP) 2009-11-26 US disclosed
US-20090291940-A1 AMINOPYRROLIDINE COMPOUND TAISHO PHARMACEUTICAL CO., LTD. (JP) 2009-11-26 US disclosed
US-20090291940-A1 AMINOPYRROLIDINE COMPOUND TAISHO PHARMACEUTICAL CO., LTD. (JP) 2009-11-26 US disclosed
EP-2003131-A1 AMINOPYRROLIDINE COMPOUND Taisho Pharmaceutical Co. Ltd. (JP) 2008-12-17 EP disclosed
US-7125995-B2 Substituted amidoalkyl uracils and their use as inhibitors of the poly(adp-ribose) synthetase (PARS) BAYER AKTIENGESELLSCHAFT (DE) 2006-10-24 US disclosed
US-20050075347-A1 Substituted amidoalkyl uracils and their use as inhibitors of the poly(adp-ribose) synthetase (pars) BAYER AKTIENGESELLSCHAFT (DE) 2005-04-07 US disclosed
EP-1339699-A1 SUBSTITUTED AMIDOALKYL URACILS AND THE USE THEREOF Bayer Aktiengesellschaft (DE) 2003-09-03 EP disclosed
WO-2002040455-A1 SUBSTITUTED AMIDOALKYL URACILS AND THEIR USE AS INHIBITORS OF THE POLY(ADP-RIBOSE) SYNTHETASE (PARS) BAYER AKTIENGESELLSCHAFT (DE) 2002-05-23 WO disclosed
WO-1988008841-A1 AMINO-4 QUINAZOLINEDIONE-5,8 DERIVATIVES, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS (FR) 1988-11-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100204226-A1 QUINAZOLINONES AS PROLYL HYDROXYLASE INHIBITORS P4HA1, EGLN3, EGLN2 NR1I3 516/4885MAPK1 1890/4885MAPT 4308/4885
US-20090291940-A1 AMINOPYRROLIDINE COMPOUND MC4R, MC5R, MC2R NR1I3 1746/4885MAPK1 1002/4885MAPT 3429/4885
US-20130216498-A1 IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS JAK1, JAK2, JAK3 NR1I3 2266/4885MAPK1 104/4885MAPT 3416/4885
US-20050075347-A1 Substituted amidoalkyl uracils and their use as inhibitors of the poly(adp-ribose) synthetase (pars) UNG, UMPS, PARP1 NR1I3 3550/4885MAPK1 2912/4885MAPT 3186/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.